Evidence map›Paper›PMID 28376113›Full record

ArticlePLoS medicine2017

Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Kevin Ten Haaf, Jihyoun Jeon, Martin C Tammemägi, Summer S Han, Chung Yin Kong, Sylvia K Plevritis, Eric J Feuer, Harry J de Koning, Ewout W Steyerberg, Rafael Meza

Erratum issued Registry-linked trialOpen access · goldAbstract readValidation Study
In one paragraph

Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06473870 (Understanding Lung Cancer Related Risk Factors and Their Impact), which is not on this map. Cited by 155 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 11 pooled it
24.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06473870 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Understanding Lung Cancer Related Risk Factors and Their Impact

Typeobservational_patient_registrySponsorBiobizkaia Health Research InstituteRan2024 to 2027Enrolled6,160ConditionsLung Cancer Screening
3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 11 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.Medical decision making : an international journal of the Society for Medical Decision Making · 2018
    Trial
  18. Trial
  19. Article
  20. Article

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Kevin Ten HaafDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jihyoun JeonDepartment of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID http://orcid.org/0000-0001-7003-3412
Martin C TammemägiDepartment of Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Summer S HanDepartment of Radiology, Stanford University, Palo Alto, California, United States of America.
Chung Yin KongDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Sylvia K PlevritisDepartment of Radiology, Stanford University, Palo Alto, California, United States of America.
Eric J FeuerDivision of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.ORCID http://orcid.org/0000-0003-4842-7751
Harry J de KoningDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Ewout W SteyerbergDepartment of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Rafael MezaDepartment of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States of America.ORCID http://orcid.org/0000-0002-1076-5037
Erasmus MC · NLStanford University · USUniversity of Michigan · USBrock University · CAMassachusetts General Hospital · USNational Cancer Institute · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Comparative Modeling of Lung Cancer Prevention and Control PoliciesU01CA199284 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2015 to 2019
$8.4M
NCI NIH HHS P30 CA124435NCI NIH HHS U01 CA199284
6 · The paper itself

Abstract

backgroundSelection of candidates for lung cancer screening based on individual risk has been proposed as an alternative to criteria based on age and cumulative smoking exposure (pack-years). Nine previously established risk models were assessed for their ability to identify those most likely to develop or die from lung cancer. All models considered age and various aspects of smoking exposure (smoking status, smoking duration, cigarettes per day, pack-years smoked, time since smoking cessation) as risk predictors. In addition, some models considered factors such as gender, race, ethnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, personal history of cancer, personal history of pneumonia, and family history of lung cancer. METHODS AND

findingsRetrospective analyses were performed on 53,452 National Lung Screening Trial (NLST) participants (1,925 lung cancer cases and 884 lung cancer deaths) and 80,672 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) ever-smoking participants (1,463 lung cancer cases and 915 lung cancer deaths). Six-year lung cancer incidence and mortality risk predictions were assessed for (1) calibration (graphically) by comparing the agreement between the predicted and the observed risks, (2) discrimination (area under the receiver operating characteristic curve [AUC]) between individuals with and without lung cancer (death), and (3) clinical usefulness (net benefit in decision curve analysis) by identifying risk thresholds at which applying risk-based eligibility would improve lung cancer screening efficacy. To further assess performance, risk model sensitivities and specificities in the PLCO were compared to those based on the NLST eligibility criteria. Calibration was satisfactory, but discrimination ranged widely (AUCs from 0.61 to 0.81). The models outperformed the NLST eligibility criteria over a substantial range of risk thresholds in decision curve analysis, with a higher sensitivity for all models and a slightly higher specificity for some models. The PLCOm2012, Bach, and Two-Stage Clonal Expansion incidence models had the best overall performance, with AUCs >0.68 in the NLST and >0.77 in the PLCO. These three models had the highest sensitivity and specificity for predicting 6-y lung cancer incidence in the PLCO chest radiography arm, with sensitivities >79.8% and specificities >62.3%. In contrast, the NLST eligibility criteria yielded a sensitivity of 71.4% and a specificity of 62.2%. Limitations of this study include the lack of identification of optimal risk thresholds, as this requires additional information on the long-term benefits (e.g., life-years gained and mortality reduction) and harms (e.g., overdiagnosis) of risk-based screening strategies using these models. In addition, information on some predictor variables included in the risk prediction models was not available.

conclusionsSelection of individuals for lung cancer screening using individual risk is superior to selection criteria based on age and pack-years alone. The benefits, harms, and feasibility of implementing lung cancer screening policies based on risk prediction models should be assessed and compared with those of current recommendations.

Indexed as

Models, TheoreticalPatient SelectionAgedEarly Detection of CancerFemaleHumansLung NeoplasmsMaleMass ScreeningMiddle AgedRetrospective StudiesRisk AssessmentRisk Factors

Identifiers

PMID28376113
PMCPMC5380315
OpenAlexW2604950454

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.